#1 Clinical Trials Search in Europe

A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)

Clinical trials investigating A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224) are studying influenza prevention in older adults. These trials aim to compare vaccine effectiveness and measure whether they lower hospitalizations due to influenza or pneumonia. The main target groups are older adults, including people aged 65 to 79 years.

Table of Contents

Trial overview

Clinical trials investigating A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224) focused on influenza prevention in older adults.[1] The studies compared high-dose quadrivalent influenza vaccine with standard-dose quadrivalent influenza vaccine to see which approach better reduced serious flu-related illness.[1][2]

Who the trials studied

One trial studied older adults in general, while the other studied adults aged 65 to 79 years in Galicia, Spain.[1][2] These are the main target populations named in the trial records.[1][2]

  • Older adults: people in later life who may have a higher risk of flu complications.[1]

  • Adults aged 65 to 79 years: a specific age group studied in the Galicia trial.[2]

Study design and phase

Both trials were interventional, which means researchers assigned participants to a vaccine group and then followed the results.[1][2] Both were Phase 3 studies, a late stage of research used to compare how well a vaccine works in large groups of people.[1][2]

The first study was a pragmatic randomized trial, which means it was designed to reflect real-world care while still using random assignment.[1] The second study was also a pragmatic randomized trial in adults 65 to 79 years in Galicia, Spain.[2]

What the trials measured

The main outcome in both studies was hospitalization due to influenza or pneumonia.[1][2] This is a composite endpoint, which means the study counted either flu hospitalization or pneumonia hospitalization as part of the same main result.[1][2]

The purpose was to measure the relative vaccine effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine.[1][2] In simple terms, the trials asked which vaccine strategy better lowered the chance of being hospitalized for flu-related illness.[1][2]

Trial status and size

One trial, NCT05517174, was completed and planned to enroll 339,700 participants.[1] The other trial, 2023-506977-36-00, was authorised and planned to enroll 114,011 participants.[2]

These are very large studies, which helps researchers compare vaccine effectiveness with more confidence.[1][2]

Key patient points

  • These trials are about preventing influenza in older adults, not treating active flu illness.[1][2]

  • The studies compare high-dose and standard-dose quadrivalent flu vaccines.[1][2]

  • The main result is whether people needed hospital care for influenza or pneumonia.[1][2]

  • Both studies are Phase 3, which means they are late-stage trials with large groups of participants.[1][2]

Trial IDPhaseCondition studiedStatusEnrollment
NCT05517174Phase 3Prevention of influenza infection in older adultsCompleted339700
2023-506977-36-00Phase 3Prevention of influenza infection in adults aged 65-79 yearsAuthorised114011

FAQ

  • What are these clinical trials studying? These trials are studying prevention of influenza infection in older adults. They compare high-dose and standard-dose quadrivalent influenza vaccines to see which works better.
  • Who can take part in the trials? The target groups are older adults, including adults aged 65 to 79 years. One trial focuses on older adults in general, and the other is in Galicia, Spain.
  • What phase are the trials in? Both trials are Phase 3 studies. Phase 3 trials usually compare treatments or vaccines in large groups of people to see how well they work.
  • What is the main result being measured? The main result is hospitalization due to influenza or pneumonia. This is a composite endpoint, which means two related outcomes are measured together.
  • How many people are in these studies? One trial planned to enroll 339,700 people, and the other planned to enroll 114,011 people. These are very large studies, which helps researchers compare vaccine effectiveness more reliably.

Ongoing Clinical Trials on A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)

  • Study on the Effectiveness of High-Dose vs. Standard-Dose Quadrivalent Influenza Vaccine in Preventing Flu in Adults Aged 65-79 in Galicia, Spain

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study Comparing High-Dose vs. Standard-Dose Influenza Vaccine for Preventing Flu in Older Adults

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • Clinical trial: A research study in people that tests a medical product or strategy to see how well it works and how safe it is.
  • Influenza: The flu, a contagious illness that affects the nose, throat, and sometimes the lungs.
  • Older adults: Adults in later life. In these trials, this includes people 65 years and older.
  • Quadrivalent influenza vaccine: A flu vaccine designed to protect against four flu strains.
  • High-dose vaccine: A vaccine with a higher amount of flu antigen, studied here against a standard-dose vaccine.
  • Standard-dose vaccine: A vaccine with the usual amount of flu antigen used for comparison in the trial.
  • Phase 3: A late stage of clinical research that compares how well a treatment works in large groups of people.
  • Interventional study: A study where researchers give a vaccine or treatment and then measure the results.
  • Composite endpoint: A main study result that combines more than one outcome, such as hospitalization for influenza or pneumonia.
  • Hospitalization: Being admitted to the hospital for medical care.